These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Benzodiazepine utilization patterns in Alzheimer's disease patients.
    Author: Lagnaoui R, Moore N, Moride Y, Miremont-Salamé G, Bégaud B.
    Journal: Pharmacoepidemiol Drug Saf; 2003 Sep; 12(6):511-5. PubMed ID: 14513664.
    Abstract:
    BACKGROUND: Benzodiazepines (BZD) are commonly prescribed in the elderly. Persons with dementia may be at a greater risk of adverse reactions of BZD such as cognitive impairment. OBJECTIVE: To assess the prevalence of BZD use in Alzheimer's disease patients and to examine patient and drug-characteristics associated with this use. DESIGN: Cross-sectional study. PARTICIPANTS: Five thousand community-dwelling and institutionalized patients initiating a treatment with tacrine for a mild to moderate Alzheimer's disease and included in the tacrine-study (Paco cohort). MEASUREMENTS: Patient characteristics and BZD use recorded at the inclusion. MAIN OUTCOME: Use of BZD during the 3 months prior to inclusion. RESULTS: The 3-month prevalence of ever use of BZD was 20%. After controlling for age and gender, there was a non-significant inverse association between BZD use and a score of Mini-Mental Status Evaluation (MMSE) below 24 (OR: 0.88, 95% CI: 0.71-1.09), and significant inverse association with an increased number of chronic conditions (OR: 0.73, 95% CI: 0.58-0.91). Higher use of BZD was associated with higher level of overall drug consumption (OR: 2.3, 95% CI: 1.97-2.80). CONCLUSION: Alzheimer's disease patients are frequently prescribed BZD. A low score of MMSE (< 24) is associated with a decreased use of BZD. These results suggest important differences in BZD use patterns among persons with Alzheimer's disease.
    [Abstract] [Full Text] [Related] [New Search]